PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED
平安健康醫療科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1833)

CHANGE OF DIRECTORS AND COMPOSITION OF BOARD COMMITTEES

The board (the "**Board**") of directors (the "**Directors**") of Ping An Healthcare and Technology Company Limited (the "**Company**") announces that, Mr. Michael Guo resigned as a non-executive Director and a member of the Nomination and Remuneration Committee of the Company, Ms. Xin Fu resigned as a non-executive Director and a member of the Sustainable Development Committee of the Company, Ms. Fangfang Cai resigned as a non-executive Director and a member of the Audit and Risk Management Committee of the Company, Dr. Wing Kin Anthony Chow resigned as an independent non-executive Director, a member of the Nomination and Remuneration Committee and the chairman of the Sustainable Development Committee of the Company, and Mr. Ziyang Zhu resigned as a non-executive Director of the Company. The above changes shall take effect from 19 August 2026.

Pursuant to the resignation letters tendered by Mr. Michael Guo, Ms. Xin Fu, Ms. Fangfang Cai, Dr. Wing Kin Anthony Chow, and Mr. Ziyang Zhu, each of them has tendered his/her resignation from the relevant positions due to his/her personal work arrangements, and each has confirmed that he/she has no disagreement with the Board nor is there any matter relating to his/her resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board is pleased to announce that Mr. Yougang Zhu ("**Mr. Zhu**") is appointed as a non-executive Director, the chairman of the Board, a member of the Audit and Risk Management Committee, and a member of the Nomination and Remuneration Committee of the Company. Mr. Tongzhuan Xi ("**Mr. Xi**") is appointed as an executive Director and a member of the Sustainable Development Committee of the Company. Ms. Yanjun Fan ("**Ms. Fan**") is appointed as a non-executive Director and a member of the Nomination and Remuneration Committee of the Company. Dr. Kwok Tung Donald Li ("**Dr. Li**") is appointed as an independent non-executive Director, a member of the Nomination and Remuneration Committee, and the chairman of the Sustainable Development Committee of the Company. The above changes shall take effect from 19 August 2026. Their initial term of office shall commence from 19 August 2026 until the first annual general meeting of the Company following their appointment, and they shall then be eligible for re-election at that meeting. The term of office for Directors re-elected by the shareholders shall commence from the date of re-election until the closure of the third annual general meeting of the Company following that date, but shall not exceed three years in total (subject to rotation and re-election in accordance with the provisions of the articles of association of the Company). Please see their biographical details set out below:

Mr. Yougang Zhu (朱友剛先生), aged 61, joined the Company as the chairman of the Board and a non-executive Director of the Company in August 2026. Mr. Zhu joined Ping An Insurance (Group) Company of China, Ltd. ("**Ping An Group**") in 1994, and is currently the Party Committee Secretary, Chairman and CEO of Ping An Health Insurance and the Party Committee Secretary and Chairman of PKU Healthcare Management Co., Ltd. Mr. Zhu has held various positions successively, including General Manager of the Anhui branch of Ping An Property & Casualty Insurance, Assistant to the General Manager of Ping An Technology, and Head of the Planning Department, Head of the Operations Division, Assistant to the General Manager, and Deputy General Manager at Ping An Property & Casualty Insurance Headquarters.

Mr. Zhu holds an EMBA degree from The Hong Kong University of Science and Technology (HKUST). Mr. Zhu also serves as a Vice President of the China Association of Gerontology and Geriatrics, a Vice President of the Health Management and Health Industry Branch of the China Association of Trade in Services, and a member of the Healthy Lifestyle Medicine Professional Committee of the National Cardiovascular Disease Expert Committee.

Mr. Tongzhuan Xi (席通專先生), aged 39, joined the Company as an executive Director and the deputy general manager in August 2026. Mr. Xi has extensive experience in management and investment. Prior to joining the Company, he held various roles within Ping An Group and its member companies, including executive director and chief financial officer of Lufax Holding from April 2025 to July 2026, deputy head of retail banking at Ping An Bank from October 2024 to April 2025, deputy director and other roles in the strategic development center and the planning department of Ping An Group from March 2023 to September 2024, and director of strategic analysis at OneConnect Financial Technology Co., Ltd. from February 2017 to July 2019. Earlier in his career, Mr. Xi worked as a consultant at PwC and McKinsey & Company from October 2012 to January 2017, and served as vice president of investment at Huaxing Growth Capital from August 2019 to February 2023, responsible for investment in financial and healthcare service industries.

Mr. Xi holds a bachelor's degree and a master's degree in Engineering from Beihang University.

Ms. Yanjun Fan (范彥君女士), aged 36, joined the Company as a non-executive Director in August 2026. Ms. Fan joined Ping An Group in May 2017, and currently serves as Vice General Manager of Ping An Group's Treasury Department. Ms. Fan has held various positions in Ping An Group's Planning Department, including manager of the Insurance Planning Office, the Comprehensive Planning Office and the Smart Finance Project Team. In these roles, she was primarily responsible for strategic planning, business performance analysis, finance and treasury management across the Group's integrated finance and health & senior care businesses. Prior to joining Ping An Group, Ms. Fan was a senior consultant at KPMG Consulting, where she advised on strategic planning, management, compliance and internal controls for large-scale cross-border projects in financial services and insurance sectors.

Ms. Fan holds a bachelor's degree in English (Translation) from Sun Yat-sen University, and a master's degree in Interpretation and Translation (Simultaneous Interpretation) from the University of Bath in the United Kingdom.

Dr. Kwok Tung Donald Li (李國棟醫生) (GBS, CStJ, JP), aged 72, joined the Company as an independent non-executive Director in August 2026. Dr. Li has been serving as an independent non-executive director of Sino Biopharmaceutical Limited (中國生物製藥有限公司, a company whose shares are listed on the Stock Exchange, stock code: 1177) since December 2020. Dr. Li is a specialist in family medicine in private practice in Hong Kong. He is a past president of the World Organization of Family Doctors (WONCA) and a past president of the Hong Kong Academy of Medicine, and is currently a censor of the Hong Kong College of Family Physicians.

Dr. Li graduated with a bachelor of Arts degree from Cornell University in the USA in 1975, followed by his medical studies at The University of Hong Kong, where he obtained a bachelor of Medicine degree in 1980. He is a Fellow of the Hong Kong College of General Practitioners, a Fellow of the Hong Kong Academy of Medicine, an Honorary Fellow of the College of Dental Surgeons of Hong Kong, an Honorary Fellow of the Royal Australian College of General Practitioners, an Honorary Fellow of the Hong Kong College of Family Physicians, a Fellow of the Faculty of Public Health of the Royal College of Physicians of the United Kingdom, an Honorary Fellow of the Academy of Family Physicians of Malaysia, a Registered Mainland China Medical Practitioner, an Honorary Fellow of the American College of Physicians, an Honorary Fellow of the Royal College of Physicians of Thailand, a Fellow of the Academy of Medicine, Singapore, an Honorary Fellow of the Royal College of Physicians of Ireland, and an Honorary Fellow of the Royal College of General Practitioners.

Dr. Li is an honorary clinical professor in Family Medicine at The Chinese University of Hong Kong, an honorary professor of Family Medicine in the Faculty of Medicine of The University of Hong Kong, and an honorary professor of Shanghai Medical College of Fudan University. He is the chairman of the Action Committee Against Narcotics, the chairman of Elderly Commission, a member of the Primary Healthcare Commission, the Council Chairman of the Hong Kong St. John Ambulance, the Chairman of Hong Kong Sheng Kung Hui Welfare Council, an honorary steward of the Hong Kong Jockey Club, and the director and honorary advisor of Jiahui Health. He is also an honorary adviser of The Hong Kong Award for Young People, an adviser of Our Hong Kong Foundation, and the chairman of the Professional Committee on Medical Health of Belt & Road General Chamber of Commerce in Hong Kong. Dr. Li was an independent non-executive director of UMP Healthcare Holdings Limited (stock code: 722) and C-MER Eye Care Holdings Limited (currently known as C-MER Medical Holdings Limited, stock code: 3309), which are listed on the Stock Exchange. In addition, Dr. Li was an independent non-executive director of New Horizon Health Limited (delisted) and resigned on 3 January 2025, which was taken over by the joint provisional liquidators on 6 August 2025.

Dr. Li has confirmed that (i) he has met the independence criteria as set out in Rule 3.13(1) to (8) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"); (ii) he has no past or present financial or other interest in the business of the issuer or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

Mr. Zhu, Mr. Xi, Ms. Fan and Dr. Li will be subject to rotation and re-election at the general meeting of the Company in accordance with the articles of association of the Company. The Company has entered into a letter of appointment with Mr. Zhu, Mr. Xi, Ms. Fan and Dr. Li, respectively, pursuant to which Mr. Zhu and Ms. Fan will not receive any Director's fee or any other emoluments; Mr. Xi will not receive any Director's fee as an executive Director during his term of office, but will receive other emoluments based on the specific executive positions, the specific amount of which will be determined by the Board as soon as practicable with reference to his qualifications, positions, responsibilities and the remuneration policy of the Company and prevailing market conditions; Dr. Li is entitled to a Director's fee of HK$450,000 per annum, which is determined by the Nomination and Remuneration Committee and the Board with reference to his qualifications, positions, responsibilities and the remuneration policy of the Company and prevailing market conditions. In addition, the standard rate is RMB10,000/meeting as working allowance for Dr. Li if attending the meetings in person (excluding meetings held by way of written communication). However, different meetings attended separately at the same time will not be counted cumulatively and will be counted as one meeting.

As at the date of this announcement, Mr. Zhu and Ms. Fan were personally interested in 59,670 and 34,784 A shares of Ping An Group (an associated corporation of the Company), respectively. In addition, Mr. Zhu and Ms. Fan held interests corresponding to 124,616 and 6,306 A shares, and 87,183 and 6,401 H shares, respectively that may be vested in the future, subject to the terms and conditions of the Long-term Service Plan of Ping An Insurance (Group) Company of China, Ltd. (the "**Long-term Service Plan**"). In addition, as at the date of this announcement, Mr. Zhu held 50,380 share options under the employee incentive scheme of the Company, was interested in 19,105 shares of the Company, and was deemed to be interested in 15,000 shares of the Company held by his spouse; Dr. Li was interested in 20,000 shares of the Company.

Save as disclosed above, as at the date of this announcement, Mr. Zhu, Mr. Xi, Ms. Fan and Dr. Li (i) had not held any other directorships in any listed public companies, in Hong Kong or overseas, in the last three years or held any other positions within the Company and its subsidiaries, and did not have any other major appointments and professional qualifications; (ii) had no relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iii) had no interests in the shares of the Company or its associated corporation within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed herein, as at the date of this announcement, there are no other matters relating to Mr. Zhu, Mr. Xi, Ms. Fan and Dr. Li that need to be brought to the attention of the holders of securities of the Company, nor is there any information required to be disclosed pursuant to the provisions of Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express its gratitude to the resigning Directors for their valuable contributions to the Company during their tenure of office and express its warm welcome to all new Directors for their new roles in the Company. The above change of Directors does not affect the normal operation of the Company. The Company believes that under the premise of scientific decision-making, the corporate governance structure of the Company will continue to be standardized and efficient after the change of Directors.

By order of the Board
Ping An Healthcare and Technology Company Limited
Michael Guo
Chairman

Shanghai, the PRC
18 August 2026

As at the date of this announcement, the Board comprises Mr. Mingke He as an executive Director; Mr. Michael Guo, Ms. Xin Fu, Ms. Fangfang Cai and Mr. Ziyang Zhu as non-executive Directors; and Mr. Yunwei Tang, Mr. Tianyong Guo and Dr. Wing Kin Anthony Chow as independent non-executive Directors.